Advanced in Chromosome 8p Deletion

Kazuteru Ohashi

Komagome, JP 
Advanced in Chromosome 8p Deletion
Komagome, JP 
OverviewLocationsClinical Research

Overview

Kazuteru Ohashi practices in Komagome, Japan. Ohashi is rated as an Advanced expert by MediFind in the treatment of Chromosome 8p Deletion. Their top areas of expertise are Graft Versus Host Disease (GvHD), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Their clinical research consists of co-authoring 279 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Chromosome 8p Deletion.

Locations

Komagome, Japan
Other Locations
Tokyo, Japan
Nagoya, 4580037, Japan
Honkomagome, 1138677, Japan
Sapporo, 0600818, Japan
Chiyoda, Japan
Bunkyo, Japan
Komagome, Japan
Tsukuba, Japan
Shizuoka, 4228526, Japan
Kashihara, Japan
Nishinomiya-hama, Japan
Yokohama, 2238522, Japan
Kashiwa, 2778561, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 3

279 Total Publications

Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
Journal: Leukemia research
Published: June 03, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ohashi's expertise for a condition
ConditionClose
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile